Renal involvement in primary Sjögren's syndrome

Rheumatology (United Kingdom)

Volumn 54, Issue 9, 2015, Pages 1541-1548

  Evans, Rhys ^a   Zdebik, Anselm ^a   Ciurtin, Coziana ^b   Walsh, Stephen B ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Autoantibodies; Autoimmune epithelialitis; B cells; Distal renal tubular acidosis; Fanconi syndrome; Hypocomplementaemia; Sj gren's syndrome; Th17 cells; Tubulointerstitial nephritis; Vasculitis

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; STEROID;

B LYMPHOCYTE; DISTAL RENAL TUBULAR ACIDOSIS; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY EPITHELIUM; KIDNEY INJURY; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DISORDER; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIMARY SJOEGREN SYNDROME; PRIORITY JOURNAL; PROXIMAL TUBULAR DYSFUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; SCREENING TEST; SJOEGREN SYNDROME; STEROID THERAPY; T LYMPHOCYTE; TUBULAR DYSFUNCTION; URINARY EXCRETION;

EID: 84983113470     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev223     Document Type: Review

References (67)

1. Sjögren H. Zur Kenntnis Der Keratoconjunctivitis Sicca Ii. Acta Ophthalmol 1935;13:1-39.
2. Ramos-Casals M, Solans R, Rosas J et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 2008;87:210-9.
3. Ioannidis JPA, Vassiliou VA, Moutsopoulos HM. Longterm risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7.
4. Moutsopoulos HM. Sjögren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5.
5. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren's syndrome: why autoimmune epithelitis? Oral Dis 2006;12:523-32.
6. Bogdanović R, Basta-Jovanović G, Putnik J, Stajić N, Paripović A. Renal involvement in primary Sjogren syndrome of childhood: case report and literature review. Mod Rheumatol 2013;23:182-9.
7. Ramos-Casals M, Brito-Zerón P, Solans R et al. Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 2014;53:321-31.
8. Jonsson R, Theander E, Sjöström B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA 2013;310:1854-5.
9. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X. Primary Sjögren syndrome. BMJ 2012;344:e3821.
10. Khan M, Merritt AD, Wohl MJ, Orloff J. Renal concentrating defect in Sjögren's syndrome. Ann Intern Med 1962;56:883-95.
11. Shearn MA, Tu W-H. Nephrogenic diabetes insipidus and other defects of renal tubular function in Sjögren's syndrome. Am J Med 1965;39:312-8.
12. Tu WH, Shearn MA, Lee JC, Hopper J. Interstitial nephritis in Sjögren's syndrome. Ann Intern Med 1968;69:1163-70.
13. Talal N, Zisman E, Schur PH. Renal tubular acidosis, glomerulonephritis and immunologic factors in Sjogren's syndrome. Arthritis Rheum 1968;11:774-86.
14. Goules AV, Tatouli IP, Moutsopoulos HM, Tzioufas AG. Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013;65:2945-53.
15. Abrol E, González-Pulido C, Praena-Fernández JM, Isenberg DA. A retrospective study of long-term outcomes in 152 patients with primary Sjögren's syndrome: 25-year experience. Clin Med 2014;14:157-64.
16. Bossini N, Savoldi S, Franceschini F et al. Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrol Dial Transplant 2001;16:2328-36.
17. Amarante GBD, Zotin MC, Rocha E et al. Renal tubular dysfunction in patients with primary Sjögren syndrome. Clin Nephrol 2014;81:185-91.
18. Aasarød K, Haga H-J, Berg KJ, Hammerstrøm J, Jørstad S. Renal involvement in primary Sjögren's syndrome. QJM 2000;93:297-304.
19. Pertovaara M, Korpela M, Kouri T, Pasternack A. The occurrence of renal involvement in primary Sjögren's syndrome: a study of 78 patients. Rheumatology 1999;38:1113-20.
20. Ren H, Wang W-M, Chen X-N et al. Renal involvement and followup of 130 patients with primary Sjögren's syndrome. J Rheumatol 2008;35:278-84.
21. Maripuri S, Grande JP, Osborn TG et al. Renal Involvement in primary Sjögren's syndrome: a clinicopathologic study. Clin J Am Soc Nephrol 2009;4:1423-31.
22. Takada K, Takiguchi M, Konno A, Inaba M. Spontaneous development of multiple glandular and extraglandular lesions in aged IQI/Jic mice: a model for primary Sjögren's syndrome. Rheumatology 2004;43:858-62.
23. Rosenberg M, Schendel P, McCurdy FA et al. Characterization of immune cells in kidneys from patients with Sjogren's syndrome. Am J Kidney Dis 1988;11:20-2.
24. Matsumura R, Kondo Y, Sugiyama T et al. Immunohistochemical identification of infiltrating mononuclear cells in tubulointerstitial nephritis associated with Sjogren's syndrome. Clin Nephrol 1988;30:335-40.
25. Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjögren's syndrome: what we know and what we should learn. J Autoimmun 2012;39:4-8.
26. Kyriakidis NC, Kapsogeorgou EK, Tzioufas AG. A comprehensive review of autoantibodies in primary Sjögren's syndrome: clinical phenotypes and regulatory mechanisms. J Autoimmun 2014;51:67-74.
27. Kapsogeorgou EK, Christodoulou MI, Panagiotakos DB et al. Minor salivary gland inflammatory lesions in Sjögren syndrome: do they evolve? J Rheumatol 2013;40:1566-71.
28. Mitsias DI, Tzioufas AG, Veiopoulou C et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 2002;128:562-8.
29. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009;175:1167-77.
30. Lin X, Rui K, Deng J et al. Th17 cells play a critical role in the development of experimental Sjögren's syndrome. Ann Rheum Dis 2015;74:1302-10.
31. Ciccia F, Guggino G, Rizzo A et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjgren's syndrome. Ann Rheum Dis 2012;71:295-301.
32. Ciccia F, Giardina A, Rizzo A et al. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Ann Rheum Dis 2013;72:782-3.
33. Van de Veerdonk FL, Lauwerys B, Marijnissen RJ et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011;63:1507-16.
34. Tzioufas AG, Tatouli IP, Moutsopoulos HM. Autoantibodies in Sjögren's syndrome: clinical presentation and regulatory mechanisms. Presse Med 2012;41(9 Pt 2):e451-60.
35. Wrong O, Davies HEF. The excretion of acid in renal disease. QJM 1959;28:259-313.
36. Walsh SB, Shirley DG, Wrong OM, Unwin RJ. Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride. Kidney Int 2007;71:1310-6.
37. Yilmaz H, Kaya M, Özbek M, Üreten K, Yildirim IS. Hypokalemic periodic paralysis in Sjögren's syndrome secondary to distal renal tubular acidosis. Rheumatol Int 2013;33:1879-82.
38. Walsh S, Turner CM, Toye A et al. Immunohistochemical comparison of a case of inherited distal renal tubular acidosis (with a unique AE1 mutation) with an acquired case secondary to autoimmune disease. Nephrol Dial Transplant 2007;22:807-12.
39. Bastani B, Haragsim L, Gluck S, Siamopoulos KC. Lack of H-ATPase in distal nephron causing hypokalaemic distal RTA in a patient with Sjögren's syndrome. Nephrol Dial Transplant 1995;10:908-9.
40. DeFranco PE, Haragsim L, Schmitz PG, Bastani B. Absence of vacuolar H(+)-ATPase pump in the collecting duct of a patient with hypokalemic distal renal tubular acidosis and Sjögren's syndrome. J Am Soc Nephrol 1995;6:295-301.
41. Nishimori I, Bratanova T, Toshkov I et al. Induction of experimental autoimmune sialoadenitis by immunization of PL/J mice with carbonic anhydrase II. J Immunol 1995;154:4865-73.
42. Takemoto F, Hoshino J, Sawa N et al. Autoantibodies against carbonic anhydrase II are increased in renal tubular acidosis associated with Sjögren syndrome. Am J Med 2005;118:181-4.
43. Takemoto F, Katori H, Sawa N et al. Induction of anticarbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjögren's syndrome. Nephron Physiol 2007;106:p63-8.
44. Khosravi M, Walsh SB. The long-term complications of the inherited tubulopathies: an adult perspective. Pediatr Nephrol 2015;30:385-95.
45. Higashi K, Kawaguchi Y, Suzuki K, Nakamura H. Sjögren's syndrome associated with hypokalemic myopathy due to Bartter's syndrome. J Rheumatol 1997;24:1663-4.
46. Pedro-Botet J, Tomas S, Soriano J, Coll J. Primary Sjögren's syndrome associated with Bartter's syndrome. Clin Exp Rheumatol 1990;9:210-2.
47. Hinschberger O, Martzolff L, Ioannou G et al. Syndrome de Gitelman acquis au cours d'un syndrome de Gougerot-Sjögren associé à une sclé rodermie. Rev Med Intern 2011;32:e96-8.
48. Kim YK, Song HC, Kim W-Y et al. Acquired Gitelman syndrome in a patient with primary Sjögren syndrome. Am J Kidney Dis 2008;52:1163-7.
49. Chen Y-C, Yang W-C, Yang A-H et al. Primary Sjögren's syndrome associated with Gitelman's syndrome presenting with muscular paralysis. Am J Kidney Dis 2003;42:586-90.
50. Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjögren's syndrome patients. Clin Rev Allergy Immunol 2007;32:265-74.
51. Mariette X, Ravaud P, Steinfeld S et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6.
52. Zandbelt MM, Wilde P de, Damme P van et al. Etanercept in the treatment of patients with primary Sjögren's syndrome: a pilot study. J Rheumatol 2004;31:96-101.
53. Dass S, Bowman SJ, Vital EM et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4.
54. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014;160:233-42.
55. Meijer JM, Meiners PM, Vissink A et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
56. Brito-Zerón P, Sisó-Almirall A, Bové A, Kostov BA, Ramos-Casals M. Primary Sjögren syndrome: an update on current pharmacotherapy options and future directions. Expert Opin Pharmacother 2013;14:279-89.
57. Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren's syndrome. Nat Rev Rheumatol 2012;8:399-411.
58. González E, Gutiérrez E, Galeano C et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008;73:940-6.
59. Clarkson MR, Giblin L, O'Connell FP et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 2004;19:2778-83.
60. Terrier B, Krastinova E, Marie I et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012;119:5996-6004.
61. Pijpe J, van Imhoff GW, Spijkervet FKL et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.
62. Devauchelle-Pensec V, Pennec Y, Morvan J et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Care Res 2007;57:310-7.
63. Brown S, Coy NN, Pitzalis C et al. The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren's syndrome. BMC Musculoskelet Disord 2014;15:21.
64. Gottenberg J-E, Cinquetti G, Larroche C et al. Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2013;72:1026-31.
65. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003;62:168-71.
66. Mariette X, Seror R, Quartuccio L et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015;74:526-31.
67. Adler S, Körner M, Förger F et al. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: a pilot study. Arthritis Care Res 2013;65:1862-8.